King's College London

Research portal

Novel Treatment Opportunities Against Cognitive Impairment in Parkinson’s Disease with an Emphasis on Diabetes-Related Pathways

Research output: Contribution to journalReview article

Holly Green, Panagiota Tsitsi, Ioanna Markaki, Dag Aarsland, Per Svenningsson

Original languageEnglish
Pages (from-to)143-160
Number of pages18
JournalCNS Drugs
Issue number2
Early online date28 Jan 2019
Publication statusPublished - 7 Feb 2019

King's Authors


Cognitive impairment is highly prevalent in patients with Parkinson’s disease (PD) and causes adverse health outcomes. Novel procognitive therapies are needed to address this unmet need. It is now established that there is an increased risk of dementia in patients with type 2 diabetes mellitus (T2DM) and, moreover, T2DM and PD may have common underlying biological mechanisms. As such, T2DM medications are emerging as potential therapies in the context of PD dementia (PDD). In this review, we provide an update on pathophysiological mechanisms underlying cognitive impairments and PDD, focusing on diabetes-related pathways. Finally, we have conducted a review of ongoing clinical trials in PD patients with dementia, highlighting the multiple pharmacological mechanisms that are targeted to achieve cognitive enhancement.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454